Synthesis of Phenyl Cinnamate and 4-Phenylchroman-2-one and Cytotoxicity Activity Test Against HeLa Cervical Cancer Cells
Keywords:
phenyl cinnamate, 4-phenylchroman-2-one, BSLT, cytotoxicity, MTT, HeLa cellsAbstract
Cinnamic acid is a derivative of methyl cinnamate; it is included in the shikimic acid pathway derivatives. Cinnamic acid and its natural analogue are known as a cancer treatment for several centuries.Synthesis of phenyl cinnamic and 4-phenilkroman-2-on derived from methyl cinnamate had been done by using acid as a catalyst. Methyl cinnamic was first converted into cinnamic acid via hydrolysis reaction with alkaline. After that, cinnamic acid was chlorinated by using thionyl chloride and phenol reagent to produce fenil-sinamat. Esterification reaction was carried out by using an acid catalyst p-toluen sulfonic acid and phenol resulting 4-phenilkroman-2-on. We obtained the products for the synthesis of cinnamic acid, cinnamic phenyl and 4-fenilkroman-2-on, with yields respectively of 83.6%, 14.71%, and 16.18%.Cytotoxicity test using the brine shrimp lethality test (BSLT) was conducted on both cinnamic phenyl compound and 4-phenilkroman-2-on compound. LC50 values obtained for both compounds respectively were 223.87 ppm and 112.72 ppm. The results of MTT cytotoxicity assay method for cervical cancer HeLa cells (ATCC CCL2) using phenyl cinnamic and 4-phenilkroman-2-on were found that the percentage of inhibition obtained is over 50%.
References
Downloads
Published
Issue
Section
License
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















